| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0079-6468(08)70157-7 |
| P698 | PubMed publication ID | 6273970 |
| P2093 | author name string | Ondetti MA | |
| Cushman DW | |||
| P2860 | cites work | A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin | Q24300463 |
| The role of the renin-angiotensin-aldosterone system in cardiovascular homeostasis in normal human subjects | Q24305000 | ||
| Substrate binding properties of converting enzyme using a series of p-nitrophenylalanyl derivatives of angiotensin I | Q28320904 | ||
| The biochemistry of the renin-angiotensin system and its role in hypertension | Q28321084 | ||
| Central cardiovascular effects of SQ 14,225, an angiotensin-converting enzyme inhibitor in chloralose-anesthetized cats | Q28321422 | ||
| Angiotensin I converting enzyme from human plasma | Q28321477 | ||
| Hypotension induced by inhibition of angiotensin-converting enzyme in pentobarbital-anesthetized dogs | Q28322092 | ||
| Potentiative effects of sulfhydryl compounds on carrageenin-induced oedema in rats and relationship to their potencies as inhibitors of angiostin-converting enzyme in vivo | Q28322189 | ||
| Converting Enzyme Inhibition Augments and Competitive Inhibition of Angiotensin II Partially Restores Reflex Adrenal Catecholamine Release in Anephric Dogs* | Q28322318 | ||
| Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats | Q28323054 | ||
| Potentiating mechanism of bradykinin action on smooth muscle by sulfhydryl compounds | Q28325832 | ||
| Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids | Q34089278 | ||
| Fate of angiotensin I in the circulation | Q34205913 | ||
| Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom | Q34206488 | ||
| Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis | Q34206989 | ||
| Inhibition by SQ 20881 of vasopressor response to angiotensin I in conscious animals | Q34207529 | ||
| Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A | Q34217732 | ||
| The preparation and function of the hypertensin-converting enzyme | Q34238210 | ||
| Subcellular distribution and properties of the bradykinin inactivation system in rabbit brain homogenates | Q34239314 | ||
| Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure | Q67391109 | ||
| Inhibition of renin secretion in the isolated rat kidney by angiotensin I | Q67391691 | ||
| Prolonged treatment of high-renin hypertension with a converting enzyme inhibitor | Q67402564 | ||
| The effect of the converting enzyme inhibitor SQ 20.881 on kinins, renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients | Q67434195 | ||
| Effect of renin‐angiotensin system on sodium intake | Q67439932 | ||
| The other angiotensins | Q67546951 | ||
| Effect of angiotensin-converting enzyme inhibitor (SQ 20881) on the plasma concentration of angiotensin I, angiotensin II, and arginine vasopressin in the dog during hemorrhagic shock | Q67652877 | ||
| Inactivation of bradykinin the plumonary circulation | Q67803826 | ||
| Angiotensin converting enzyme: method of assay and partial purification | Q68605093 | ||
| Studies on the angiotensin converting enzyme with different substrates | Q68608796 | ||
| Inhibition of angiotensin I converting enzyme and kininase in rabbit plasma by bradykinin potentiating peptide B (Pyr-Gly-Leu-Pro-Arg-Pro-Lys-Ile-Pro-Pro) | Q68632310 | ||
| Inhibition of angiotensin I-initiated hemodynamic changes in anesthetized dogs by a synthetic nonapeptide | Q68642843 | ||
| Angiotensin I converting enzyme of calf lung. Method of assay and partial purification | Q68644503 | ||
| Purification and properties of angiotensin-converting enzyme from hog lung | Q68647267 | ||
| Effect of a converting enzyme inhibitor (SQ 20,881) on angiotensin-induced drinking | Q68653952 | ||
| Effects of angiotensin I and antiotensin II on canine hepatic vascular resistance | Q68654564 | ||
| Stimulation of splenic prostaglandin release by angiotensin and specific inhibition by cysteine 8-AII | Q68658034 | ||
| Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca | Q68662321 | ||
| Inhibition of angiotensin-coverting enzyme by analogs of peptides from Bothrops jararaca venom | Q68668089 | ||
| Bradykinin potentiating peptide PCA-Lys-Trp-Ala-Pro. An inhibitor of the pulmonary inactivation of bradykinin and conversion of angiotensin I to II | Q68669024 | ||
| Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung | Q68669025 | ||
| Effects of angiotensin I and angiotensin II on hindlimb and coronary vascular resistance | Q68669167 | ||
| Hydrolysis of bradykinin by angiotensin-converting enzyme | Q68686336 | ||
| Effect of blockade of angiotensin-I converting enzyme on the blood pressure of renal hypertensive rabbits | Q68703286 | ||
| On the role of vasopressin and angiotensin in the development of irreversible haemorrhagic shock | Q68704129 | ||
| studies of plasma bradykininases using radiolabelled substrates | Q68706866 | ||
| Angiotensin-converting enzyme from porcine plasma | Q68713088 | ||
| Effect of a renal prostaglandin on distribution of blood flow in the isolated canine kidney | Q69775419 | ||
| Letter: Hypotension during administration of angiotensin converting enzyme inhibitor SQ 20,881 | Q70022577 | ||
| Structure of bradykinin-potentiating peptide containing tryptophan from the venom ofAgkistrodon halys blomhoffii | Q71726060 | ||
| Characteristics and Significance of Prodromes of Coronary Care Unit Patients | Q71751191 | ||
| Potentiation of the cerebral vascular action of bradykinin by the 'bradykinin potentiating factor' (BPF) in the dog | Q72662866 | ||
| Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom | Q72668344 | ||
| Greene LL, Ferreira SH: Potential screening test for detection of overactivity of renin-angiotensin system | Q93695904 | ||
| Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme | Q93731616 | ||
| Effect of angiotensin-converting enzyme inhibitor on response of plasma renin activity and aldosterone to tilting in man. | Q34451342 | ||
| The existence of two forms of hypertensin | Q34648778 | ||
| Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme | Q34698149 | ||
| Inhibition of angiotensin I converting enzyme by venom peptides | Q34698491 | ||
| An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients | Q34698738 | ||
| Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents | Q34936463 | ||
| Mechanism and modification of bradykinin-induced coronary vasodilation | Q35080604 | ||
| The effect of angiotensin I converting enzyme inhibitor (SQ 20881) on the release of prostaglandins by rabbit kidney, in vivo | Q35176470 | ||
| Pulmonary metabolism of bradykinin analogues and the contribution of angiotensin converting enzyme to bradykinin inactivation in isolated lungs | Q35176902 | ||
| The renin-angiotensin-aldosterone system in congestive failure in conscious dogs | Q35202042 | ||
| Modification of responses to sympathetic nerve stimulation by the renin-angiotensin system in rats | Q35603306 | ||
| Role of extrapulmonary conversion in mediating the systemic pressor activity of angiotensin I. | Q36273600 | ||
| Biological and biochemical properties of angiotensin-converting enzyme | Q37112975 | ||
| Converting enzyme inhibition and blood pressure regulation | Q37113027 | ||
| Angiotensin-Converting Enzyme and the Regulation of Vasoactive Peptides | Q37116751 | ||
| Renin-angiotensin system: biochemistry and mechanisms of action | Q37382695 | ||
| Angiotensin-converting enzyme from rabbit pulmonary particles | Q37442746 | ||
| Regulation of aldosterone secretion by the renin-angiotensin system during sodium restriction in rats | Q37593464 | ||
| Escherichia coli mutants defective in dipeptidyl carboxypeptidase | Q37596321 | ||
| The renin system in high blood pressure, from disbelief to reality: Converting-enzyme blockade for analysis and treatment | Q37863779 | ||
| Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzyme | Q37863817 | ||
| Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agent | Q37863825 | ||
| Kinetic properties of pulmonary angiotensin-converting enzyme. Hydrolysis of hippurylglycylglycine | Q39087186 | ||
| The effects of angiotensin I and angiotensin II on the isolated tracheal muscle of the cat | Q39099201 | ||
| Renal Angiotensin I-Converting Enzyme as a Mixture of Sialo- and Asialo-enzyme, and a Rapid Purification Method | Q39117695 | ||
| Modern system for treating high blood pressure based on renin profiling and vasoconstriction-volume analysis: A primary role for beta blocking drugs such as propranolol | Q39119930 | ||
| Response to angiotensins I and II and to AI-converting-enzyme inhibitor in a shark | Q39129533 | ||
| Purification of angiotensin I-converting enzyme from human lung | Q39158466 | ||
| Equine angiotensin converting enzyme: a zinc metalloenzyme | Q39159015 | ||
| A fluorogenic substrate for angiotensin-converting enzyme | Q39171105 | ||
| Substance P degradation by rat brain peptidases: inhibition by SQ 20881. | Q39242200 | ||
| A specific orally active inhibitor of angiotensin-converting enzyme in man. | Q39429288 | ||
| Correction of renal hypertension in the rat by prolonged infusion of angiotensin inhibitors | Q39472653 | ||
| Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure | Q39507490 | ||
| Effects of SQ 14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs | Q40183347 | ||
| Chronic antihypertensive effects of captopril (SQ 14,225), an orally active angiotensin I-converting enzyme inhibitor, in conscious 2-kidney renal hypertensive rats | Q40183353 | ||
| Drinking in water deprived rats after combined central angiotensin receptor and converting enzyme blockade | Q40186122 | ||
| Peptidyl dipeptidase in rabbit brain microvessels | Q40188024 | ||
| Angiotensin-converting enzyme: Presence of high activity in choroid plexus of mammalian brain | Q40189063 | ||
| Studies on the hydrolysis of bradykinin by angiotensin-converting enzyme (kininase II) | Q40189150 | ||
| Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients | Q40192276 | ||
| Peptide inhibitors of angiotensin I-converting enzyme in digests of gelatin by bacterial collagenase | Q40196323 | ||
| Inhibition of the renin-angiotensin-system in brattleboro rats with hereditary hypothalamic diabetes insipidus | Q40199535 | ||
| Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive Patients | Q40207778 | ||
| The effects of kininase II inhibition by SQ 14225 on kidney kallikrein-kinin and prostaglandin systems in conscious dogs | Q40216628 | ||
| Hemodialysis-Resistant Hypertension: Control with an Orally Active Inhibitor of Angiotensin-Converting Enzyme* | Q40217788 | ||
| Effect of Angiotensin Converting Enzyme Inhibition on Blood Pressure, Plasma Renin Activity and Plasma Aldosterone in Essential Hypertension * | Q40224866 | ||
| Modification by SQ 14225 of blood pressure and adrenal catecholamine response to hemorrhage | Q40237895 | ||
| Action of Angiotensin I Converting Enzyme Inhibitor on the Control of Renal Function in the Cat | Q40251816 | ||
| Mechanism of angiotensin I converting enzyme inhibition by SQ20,881 (less than Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo. Further evidence for extrapulmonary conversion | Q40294571 | ||
| Converting enzyme inhibition with an orally active compound in hypertensive man | Q40294575 | ||
| Prior receptor occupancy as a determinant of the pressor activity of infused angiotensin II in the rat | Q40308391 | ||
| Inhibition of angiotensin conversion and prevention of renal hypertension | Q40310776 | ||
| The role of the renin-angiotensin system in the initiation of renovascular hypertension | Q40670045 | ||
| Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia. Effects on systemic hemodynamics, regional blood flows, and tissue metabolism | Q40688762 | ||
| Hemodynamic characteristics of hypertension after coronary bypass surgery and effects of the converting enzyme inhibitor | Q40702845 | ||
| The mechanism of action of two bradykinin-potentiating peptides on isolated smooth muscle | Q41011679 | ||
| Adrenal Responses to Pharmacological Interruption of the Renin-Angiotensin System in Sodium-Restricted Normal Man* | Q41022879 | ||
| Prolongation of the saralasin responsive state of two-kidney, one clip Goldblatt hypertension in the rat by the orally administered converting enzyme inhibitor captopril (SQ14,225) | Q41187217 | ||
| Converting Enzyme Inhibition in Hypertensive Emergencies | Q41437183 | ||
| Synthesis and pharmacology of a prohormone angiotensin antagonist | Q41445544 | ||
| Design of potent and specific inhibitors of carboxypeptidases A and B | Q41482450 | ||
| Angiotensin-Converting Enzyme Inhibitor (SQ 20881) in the Diagnosis of Renovascular Hypertension | Q41536202 | ||
| The role of angiotensin in the canine renal vascular response to barbiturate anesthesia | Q41784310 | ||
| Hydrolysis of bradykinin and its higher homologues by angiotensin-converting enzyme | Q41862200 | ||
| Effect of converting enzyme blockade on isoprenaline- and angiotensin I-induced drinking | Q41912640 | ||
| Angiotensin blockade: its clinical significance | Q42001746 | ||
| The bradykininase activities of extracts of dog lung | Q43002601 | ||
| Inhibitors of the pulmonary angiotensin I-converting enzyme | Q43468107 | ||
| Effect of the inhibition of angiotensin I converting enzyme in endotoxin and hemorrhagic shock. | Q43725310 | ||
| Evidence for myocardial conversion of angiotensin I. | Q43918557 | ||
| Conversion of angiotensin I into angiotensin II in the isolated perfused rat kidney | Q43938264 | ||
| In vitro study on the effects of bradykinin potentiating factor and angiotensin II analogue on degradation and conversion of angiotensin I and II in plasma | Q43938789 | ||
| The effects of angiotensin II blockade in conscious sodium-depleted dogs | Q43973249 | ||
| Metabolism of the angiotensins in isolated perfused tissues | Q43983009 | ||
| Effects of Diphenylhydantoin on Excitability and Automaticity in the Canine Heart | Q44046281 | ||
| Bradykinin potentiating and sensitizing activities of new synthetic analogs of snake venom peptides | Q44052825 | ||
| Alkylating analogs of peptide hormones. 1. Synthesis and properties of p-(N,N-)-bis(2-chloroethyl)amino)phenylbutyryl derivatives of bradykinin and bradykinin potentiating factor | Q44089793 | ||
| Effect of the synthetic peptide, Sq 20,881, on distribution of blood flow in the rat. | Q44105991 | ||
| Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor | Q44137963 | ||
| Letter: Hypotensive effect of angiotensin-converting-enzyme inhibitor SQ 20,881. | Q44184476 | ||
| Angiotensin and thirst: studies with a converting enzyme inhibitor and a receptor antagonist | Q44210833 | ||
| Contractile Responses to Angiotensin l and Angiotensin II in Hamster Uterine Smooth Muscle | Q44493250 | ||
| Des-Asp1-angiotensin I: a metabolite of angiotensin I in the perfused feline adrenal | Q44629775 | ||
| Continuous angiotensin II blockade throughout the acute phase of one-kidney hypertension in the dog | Q44789325 | ||
| Specific stimulation and inhibition of renal prostaglandin release by angiotensin analogs | Q45049275 | ||
| The cost of scientific communication: the scientist as ad-man | Q45099384 | ||
| Renal vascular response to interruption of the renin-angiotensin system in normal man | Q45796029 | ||
| Structure-activity relationships of bradykinin potentiating peptides | Q46151311 | ||
| Bradykinin-potentiating peptides from the venom of Agkistrodon halys blomhoffi. Isolation of five bradykinin potentiators and the amino acid sequences of two of them, potentiators B and C. | Q46438588 | ||
| Structure of potentiator A, one of the five bradykinin potentiating peptides from the venom of Agkistrodon halys blomhoffii | Q46491129 | ||
| The renin--angiotensin system: inhibition of converting enzyme in isolated tissues | Q46596530 | ||
| New sulfhydryl compounds with potent antihypertensive activities | Q46606977 | ||
| In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III | Q46678742 | ||
| Bradykinin-potentiating peptides from the venom ofAgkistrodon halys blomhqffii | Q46756248 | ||
| The bradykinin potentiating activity of two pentapeptides on various isolated smooth muscle preparations | Q46759206 | ||
| Peptide inhibitors of pulmonary angiotensin I converting enzyme | Q46868311 | ||
| Application of mass spectrometry to sequence analysis of pyroglutamyl peptides from snake venoms: contribution to the confirmation of the amino acid sequence of bradykinin-potentiating peptides B, C and E isolated from the venom of Agkistrodon halys | Q47924592 | ||
| Improvement of chronic congestive heart-failure by oral captopril | Q39550043 | ||
| Autonomic neural influences on the dysrhythmias resulting from myocardial infarction | Q39725287 | ||
| Agents which block the action of the renin-angiotensin system | Q39900497 | ||
| Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation | Q39902030 | ||
| Angiotensin-converting enzyme in human brain | Q39933249 | ||
| Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition | Q39942256 | ||
| Formation of angiotensin II from tetradecapeptide renin substrate by angiotensin-converting enzyme | Q39946397 | ||
| Elevation of serum angiotension-converting-enzyme (ACE) level in sarcoidosis | Q39950095 | ||
| Increase in cyclic AMP levels and vasopressin release in response to angiotensin I in neurohypophyses: Blockade following inhibition of the converting enzyme | Q39963399 | ||
| Synthesis and evaluation of [des-Asp1]angiotensin I as a precursor for [des-Asp1]angiotensin II (angiotensin III) | Q39963512 | ||
| The Inhibition of Angiotensin Converting Enzyme in Chronic Renal Hypertension by a Synthetic Peptide | Q39970321 | ||
| Elevation of Serum Angiotensin-Converting Enzyme in Gaucher's Disease | Q39991377 | ||
| The inactivation of bradykinin in the pulmonary circulation of isolated lungs | Q39994147 | ||
| Formation of angiotensin III by angiotensin-converting enzyme | Q40000291 | ||
| Carboxypeptidase A: a protein and an enzyme. | Q40005857 | ||
| Angiotensin I-converting enzyme from guinea pig lung and serum. A comparison of some kinetic and inhibition properties | Q40006349 | ||
| Correlation of pulmonary structure with pharmacokinetic function | Q40012099 | ||
| Similarity in some properties of serum angiotensin converting enzyme from sarcoidosis patients and normal subjects | Q40013578 | ||
| Role of Converting Enzyme in the Cardiovascular and Adrenal Cortical Responses to (des-Asp)-Angiotensin I | Q40016878 | ||
| Action of bradykinin potentiating factor (BPF) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestines | Q40017862 | ||
| Vascular angiotensin receptors and their role in blood pressure control | Q40024590 | ||
| Estimating renin participation in hypertension: Superiority of converting enzyme inhibitor over saralasin | Q40024598 | ||
| Solubilization of angiotensin I-Converting enzyme from rabbit lung using trypsin treatment | Q40025790 | ||
| The Renin-Angiotensin System and Thirst: A Reevaluation | Q40029278 | ||
| (Des-Asp1) Angiotensin I: A Study of its Pressor and Steroidogenic Activities in Conscious Rats* | Q40032280 | ||
| Endocrine and Cardiovascular Consequences of Angiotensin Converting Enzyme Inhibition | Q40048963 | ||
| Possible Role of Renin in Hypertension as Suggested by Renin-Sodium Profiling and Inhibition of Converting Enzyme | Q40052344 | ||
| Effect of intrarenal angiotensin II blockade on renal function in conscious dogs | Q40057167 | ||
| Some enzymatic properties of peptidyl dipeptide hydrolase (angiotensin I-converting enzyme). | Q40058631 | ||
| Dose response of SQ 20,858 in chronic renal hypertension | Q40075460 | ||
| Accentuated Vascular and Endocrine Response to Sq 20881 in Hypertension | Q40080419 | ||
| Rabbit tissue peptidases that hydrolyse the peptide hormone bradykinin. Differences in enzymic properties and concentration in rabbit tissues | Q40082692 | ||
| Peptide inhibitors of converting enzyme | Q40108103 | ||
| Effect of the inhibitor of angiotensin i converting enzyme on endocrine function and renal perfusion in haemorrhagic shock | Q40116713 | ||
| Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits | Q40117360 | ||
| Properties of three different forms of angiotensin I-converting enzyme from human lung | Q40122289 | ||
| Effects of the Oral Converting Enzyme Inhibitor (SQ 14225) on One-Kidney Hypertension in the Dog | Q40125982 | ||
| Soluble dextran complexes of Kallikrein, Bradykinin and enzyme inhibitors | Q40127777 | ||
| Inhibition of Angiotensin-Converting Enzyme for Diagnosis of Renal-Artery Stenosis | Q40130936 | ||
| Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in Man | Q40141803 | ||
| Subcellular localization and partial purification of a chloride dependent angiotensin-I converting enzyme from rat brain | Q40146562 | ||
| Inhibition of brain angiotensin-1 converting enzyme by Bothrops jararaca nonapeptide (SQ 20881) and a prolyl analog (SQ 14225) | Q40160400 | ||
| Beneficial action of new angiotensin-converting enzyme inhibitor (SQ 14,225) in hemorrhagic shock in cats | Q40170709 | ||
| Functional residues at the active site of angiotensin converting enzyme | Q40176791 | ||
| Intestinal vasoconstriction following diuretic-induced volume depletion: role of angiotensin and vasopressin | Q48536116 | ||
| Drinking induced by injections of angiotensin into forebrain and mid-brain sites of the monkey | Q48553560 | ||
| Inhibition of central pressor effects of agiotensin I and II. | Q48568697 | ||
| Renin-angiotensin role in thirst: paradoxical enhancement of drinking by angiotensin converting enzyme inhibitor | Q48612826 | ||
| Differential distribution of angiotensin converting enzyme in the anterior and posterior lobe of the rat pituitary | Q48629202 | ||
| Angiotensin I as a dipsogen: efficacy in brain independent of conversion to angiotensin II. | Q48648635 | ||
| Characterization of central angiotensin II receptors involved in the elicitation of drinking in the rat. | Q48686756 | ||
| Distribution and properties of angiotensin converting enzyme of rat brain | Q48724652 | ||
| Antinociceptive action of intraventricular bradykinin | Q51117182 | ||
| Concentrations of angiotensin-converting enzyme in tissues of the rat. | Q51120575 | ||
| Angiotensin-converting enzyme from guinea pig and hog lung. | Q52996248 | ||
| Human plasma converting enzyme. | Q53735315 | ||
| Inhibition of angiotensin conversion in experimental renovascular hypertension. | Q53786150 | ||
| Contribution of intrarenal generation of prostaglandin to autoregulation of renal blood flow in the dog. | Q53791563 | ||
| Carboxycathepsin--a key regulatory component of two physiological systems involved in regulation of blood pressure. | Q53814616 | ||
| Synthesis and properties of new bradykinin potentiating peptides | Q53999813 | ||
| Cleavage of active peptides by a lung enzyme. | Q54037130 | ||
| Substrate specificity of hog plasma angiotensin-converting enzyme. | Q54146130 | ||
| Conversion of angiotensin I to angiotensin II in the canine mesenteric circulation. | Q54312632 | ||
| Angiotensin I-converting enzyme of the kidney cortex. | Q54600740 | ||
| Bradykinin analogs containing .beta.-homoamino acids | Q54624709 | ||
| Effect of angiotensin converting enzyme inhibition on renal autoregulation. | Q54637638 | ||
| Inhibition of converting enzyme of the renin-angiotensin system in kidneys and hindlegs of dogs. | Q54642466 | ||
| Intrarenal conversion of angiotensin I to angiotensin II in the dog. | Q54665383 | ||
| Pharmacology of antagonists of angiotensin I and II. | Q54704240 | ||
| Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung | Q59076950 | ||
| Experiment to detect Pulsed γ-Rays from the Crab Nebula | Q59076955 | ||
| Conversion of angiotensin I to angiotensin II | Q66846278 | ||
| Role of converting enzyme in the responses of rabbit atria, aortas, and adrenal zona glomerulosa to [des-Asp1]angiotensin I | Q66846864 | ||
| Failure of renin suppression by angiotensin II in hypertension | Q67242144 | ||
| Slow conduction and reentry in the ventricular conducting system. II. Single and sustained circus movement in networks of canine and bovine Purkinje fibers | Q67269442 | ||
| Paradoxical inhibition of the effects of bradykinin by some sulfhydryl reagents | Q67298594 | ||
| Mechanism of blood pressure reduction by teprotide (SQ 20881) in rats | Q67330950 | ||
| Hydrolysis of enkephalin by cultured human endothelial cells and by purified peptidyl dipeptidase | Q67338698 | ||
| Quantitative analysis of the acute response to haemorrhage of the renin-angiotensin-vasoconstrictor feedback loop in areflexic dogs | Q67353062 | ||
| Angiotensin converting enzyme inhibition in patients with congestive heart failure | Q67391111 | ||
| P304 | page(s) | 41-104 | |
| P577 | publication date | 1980-01-01 | |
| P1433 | published in | Progress in medicinal chemistry | Q27712806 |
| P1476 | title | Inhibitors of angiotensin-converting enzyme | |
| P478 | volume | 17 |
| Q43773521 | A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies |
| Q67915438 | Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action |
| Q34236623 | Angiotensin-converting enzyme inhibitors |
| Q51764192 | Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases. |
| Q70592568 | Cardiovascular and sympathoadrenal responses to intrathecal injection of neuropeptide K in the conscious rat |
| Q47698974 | Chloride binding proteins: mechanistic implications for the oxygen-evolving complex of Photosystem II. |
| Q42087362 | Converting enzyme activity of free airway cells |
| Q72404980 | Design of conformationally constrained angiotensin-converting enzyme inhibitors |
| Q72914313 | Design of protease inhibitors |
| Q42243169 | Development and design of specific inhibitors of angiotensin-converting enzyme |
| Q35811130 | Digestion and assimilation of proline-containing peptides by rat intestinal brush border membrane carboxypeptidases. Role of the combined action of angiotensin-converting enzyme and carboxypeptidase P. |
| Q82604898 | Effects of intravenous urocortin on angiotensin-converting enzyme in rats |
| Q43228807 | Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts |
| Q36997833 | Human lung angiotensin converting enzyme. Purification and antibody preparation |
| Q72664858 | Inhibitors of the Renin-Angiotensin System as New Antihypertensive Agents |
| Q73501558 | Liquid chromatographic determination of hippuric acid for the evaluation of ethacrynic acid as angiotensin converting enzyme inhibitor |
| Q36289138 | Phosphorus-containing inhibitors of angiotensin-converting enzyme |
| Q77749190 | Probing the importance of spacial and conformational domains in captopril analogs for angiotensin converting enzyme activity |
| Q73613770 | Pyrrolidine as a cogwheel-like scaffold for the deployment of diverse functionality through cycloaddition reactions of metallo-1,3-dipoles in aqueous media |
| Q40979088 | Renin inhibition: a novel therapy for cardiovascular disease |
| Q70942045 | Renin inhibitors |
| Q72390630 | Renin- and non-renin–mediated antihypertensive actions of converting enzyme inhibitors |
| Q34255117 | The Catalytic Mechanism of Angiotensin Converting Enzyme |
Search more.